TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00420472
Drug: mycophenolate mofetil [CellCept]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02770664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02770664
Drug: LC28-0126 Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC28-0126 Dose A
Study: NCT02770664
Drug: LC28-0126 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC28-0126 Dose B
Study: NCT00116870
Drug: lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00819910
Drug: Placebo (Rosiglitazone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Rosiglitazone) 8mg daily for 12 weeks
Study: NCT00819910
Drug: Placebo (Fenofibrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Fenofibrate) 145 mg daily for 12 weeks
Study: NCT00650572
Drug: ARRY-380, HER2 inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
Study: NCT00932867
Drug: Kinzal/Pritor (Telmisartan, BAY68-9291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients under daily life treatment receiving Pritor according to local drug information.
Study: NCT02023684
Drug: control saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical bed irrigation with saline 40ml
Study: NCT00506545
Drug: Placebo Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
Study: NCT00389519
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day oral placebo capsule for 4 weeks
Study: NCT05167123
Drug: Light cured tri-calcium silicate base material
Normalized name: Calcium Silicate
DrugBank: Calcium silicate (DB13829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe
Study: NCT03772964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be exposed to placebo, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
Study: NCT00099515
Drug: LY041001 (HIIP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation, capsule, TID 3 times per day min 6 IU max 60 IU
Study: NCT00099515
Drug: LY041001 (HIIP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation, Capsule, TID 3 times per day min 6 IU max 60 IU
Study: NCT00391950
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01674777
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01938040
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single preoperative dose prior to surgery
Study: NCT02828930
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to idasanutlin aqueous dispersion will be administered orally on Day 11.
Study: NCT01030679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, 1 tablet once daily for 8 weeks
Study: NCT02170870
Drug: Microlipid
Normalized name: Microlipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
Study: NCT02170870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion will be prepared to match the appearance of Exendin 9-39
Study: NCT01868113
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days
Study: NCT03224325
Drug: TAK-831 Tablet T2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tak-831 tablets.
Study: NCT03224325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-831 placebo-matching suspension.
Study: NCT01889056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution
Study: NCT02259998
Drug: Persantin® new formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02259998
Drug: Persantin® commercial formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02693041
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
Study: NCT01549054
Drug: 10-mg dose of E5501-P21% powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension
Study: NCT00161447
Drug: Testosterone Gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone Gel (10 g daily
Study: NCT01928901
Drug: administration of Sinupret Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01928901
Drug: administration of Bronchipret Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005825
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03482037
Drug: Rec 0/0438 1 mg or Rec 0/0438 2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each vial content will be administered via the catheter used for the self-catheterization
Study: NCT03482037
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each vial content will be administered via the catheter used for the self-catheterization
Study: NCT04442984
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1 Leucovorin 400 mg every two weeks
Study: NCT03837925
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient participation for 6 weeks of treatment
Study: NCT02772614
Drug: BIA 3-202 (200 mg)
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg powder for oral use of unlabelled BIA 3-202
Study: NCT03521323
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos: Saline，Sham operation
Study: NCT01606384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study: NCT02767375
Drug: Oxaliplatin(OXA), 5-fluorouracil (5-FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 \& 2 , IA，q4-6 Weeks
Study: NCT03045523
Drug: GLPG2222 150 mg q.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
Study: NCT03045523
Drug: GLPG2222 300 mg q.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
Study: NCT03045523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
Study: NCT04147325
Drug: Antiretroviral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.
Study: NCT02206035
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m\^2 Days +3, +6 and +11.
Study: NCT00751842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected subcutaneously at days 1, 30, 90 and 270.
Study: NCT00928174
Drug: IV administration of fluorine-18 fluorocholine followed by PET/CT imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.
Study: NCT01339741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral route, 12 weeks
Study: NCT03478163
Drug: Clindamycin 900 MG in 6 ML Injection
Normalized name: clindamycin 900 MG in 6 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 900 mg every 8 hours for 3 doses
Study: NCT02292043
Drug: HTEA
Normalized name: Hydrocortisone Tetraacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTEA
Study: NCT05301010
Drug: Faceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
Study: NCT04063163
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01340053
Drug: RDX5791
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, QD
Study: NCT02580591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For blinding purposes
Study: NCT01124162
Drug: Cozaar®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Tablet
Study: NCT01176799
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles
Study: NCT02273414
Drug: BIIL 284 BS - rising dose
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02273414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01176799
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
Study: NCT00802009
Drug: Mepivicaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anesthetic solution administered during routine brachial plexus nerve blockade.
Study: NCT01966289
Drug: CY
Normalized name: CYT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CY is administered intravenously at 200 mg/m2
Study: NCT03594331
Drug: High-dose PvP001
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose PvP001
Study: NCT03594331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL liquid with no drug
Study: NCT02534896
Drug: Treatment I
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunpharma1505 and Placebo
Study: NCT02534896
Drug: Treatment II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunpharma1505 and Placebo
Study: NCT02534896
Drug: Treatment III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference1505 and Placebo
Study: NCT01641809
Drug: GSK1265744 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
Study: NCT00465751
Drug: chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chenodeoxycholic acid 500 mg capsules tid po
Study: NCT00465751
Drug: placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules containing mannitol tid po
Study: NCT01641809
Drug: GSK1265744 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
Study: NCT01641809
Drug: GSK1265744 60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
Study: NCT01641809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
Study: NCT01891435
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: after giving medicine temperature is checked every 30 minutes for 2 hours
Study: NCT01891435
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: after giving medicine temperature is checked every 30 minutes for 2 hours
Study: NCT01891435
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: after giving medicine temperature is checked every 30 minutes for 2 hours
Study: NCT00245037
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This drug is used to prevent seizures while on chemotherapy.
Study: NCT00245037
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.
Study: NCT01717768
Drug: TSX-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSX-002 are capsules with testosterone as the active ingredient.
Study: NCT00078754
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine capsules by mouth, up to 60 mg daily
Study: NCT00330850
Drug: PRO-513
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03346941
Drug: DAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral-based treatment
Study: NCT01561742
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline will be given orally at 200 mg a day for 4 months
Study: NCT01561742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: EquivalentPlacebo will be given
Study: NCT01032382
Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application to CL lesions once daily for 20 days
Study: NCT01032382
Drug: Paromomycin Alone Cream (15% paromomycin topical cream)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application to CL lesions once daily for 20 days
Study: NCT01051700
Drug: GW786034
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product
Study: NCT02823626
Drug: Spironolactone and patiromer
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose spironolactone with or without patiromer based on the patient's baseline potassium
Study: NCT00635726
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate intravenous (IV) 30 mgr/m2 on day 1 every 2 weeks for 6 courses
Study: NCT00635726
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV 30 mgr/m2 on day 2 every 2 weeks for 6 courses
Study: NCT02564939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: double-blind RCT
Study: NCT03570541
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every six hours postoperative, all patients are administered 1 g of acetaminophen.
Study: NCT04124705
Drug: Armour® Thyroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once a day. the daily dose could range from 1/4 - 2 grains.
Study: NCT04124705
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally once a day; the daily dose could range from 25- 200 µg.
Study: NCT01436474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
Study: NCT02821468
Drug: Droglican
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg
Study: NCT00209703
Drug: l-Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03595592
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin will be delivered i.v. on day 1 every 3 weeks in arm ACy followed by HPCT for the first 3 cycles
Study: NCT03595592
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab for the first 3 cycles
Study: NCT01283698
Drug: Reference
Normalized name: Loreal Preference Dark Auburn 4R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator,once daily
Study: NCT01973998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive substance.
Study: NCT00722956
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg once daily, 10 days
Study: NCT00042406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered as a subcutaneous infusion twice (BID) with 2 weeks interval followed by administration every 4 weeks up to Week 22.
Study: NCT02877303
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02877303
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00564018
Drug: NPH
Normalized name: ZENPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
Study: NCT02877303
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02877303
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV, and PO
Study: NCT04115098
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study: NCT04115098
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study: NCT04115098
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study: NCT01702246
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg, orally, once daily for 3 months
Study: NCT01597713
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of oral placebo within each dose group
Study: NCT03161522
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
Study: NCT03161522
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
Study: NCT02259907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02896504
Drug: Exposure: Adjuvant chemotherapy treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00312533
Drug: Hylan F- 20
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03933774
Drug: Tretinoin 0.05% cream
Normalized name: TRETINOIN 0.05% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stieva-A Cream 0.05%, 25g, GSK
Study: NCT03933774
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel
Study: NCT02411578
Drug: G-Pen Mini™ (glucagon injection)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 150 µg of glucagon~2. BG is 40-49 mg/dl, treatment is 300 µg of glucagon~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 150 µg of glucagon~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is \>=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(150 µg of glucagon per syringe)
Study: NCT03787225
Drug: NNC0174-0833
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.
Study: NCT03787225
Drug: Placebo (NNC0174-0833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive NNC0174-0833 matched placebo subcutaneously.
Study: NCT01241097
Drug: simvastatin, combined with simvastatin ezetimibe, placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
Study: NCT02440243
Drug: Purethal
Approvals — FDA: no, EMA: no, PMDA: no
Description: prerseasonal course of SCIT - three years